<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Angiotensin-converting enzyme (ACE) inhibitors and receptor antagonists for treatment of adults with hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Angiotensin-converting enzyme (ACE) inhibitors and receptor antagonists for treatment of adults with hypertension</h1>
<div class="graphic"><div class="figure"><div class="ttl">Angiotensin-converting enzyme (ACE) inhibitors and receptor antagonists for treatment of adults with hypertension</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">US brand (trade) name</td> <td class="subtitle1">Usual oral daily dose range (mg)*<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">ACE inhibitors</td> </tr> <tr> <td class="indent1">Benazepril</td> <td>Lotensin</td> <td>10 to 40 (maximum 80 mg)</td> </tr> <tr> <td class="indent1">Captopril</td> <td>Capoten<br/> (only available in US as generic preparation)</td> <td>25 to 150 in two or three divided doses</td> </tr> <tr> <td class="indent1">Cilazapril<sup>Δ</sup></td> <td>Inhibace<br/> (Canadian trade name)</td> <td>2.5 to 5</td> </tr> <tr> <td class="indent1">Enalapril</td> <td>Vasotec</td> <td>10 to 40</td> </tr> <tr> <td class="indent1">Fosinopril</td> <td>Monopril<br/> (only available in US as generic preparation)</td> <td>10 to 40 (maximum 80 mg)</td> </tr> <tr> <td class="indent1">Lisinopril</td> <td>Prinivil, Zestril</td> <td>10 to 40</td> </tr> <tr> <td class="indent1">Moexipril</td> <td>Univasc</td> <td>7.5 to 30</td> </tr> <tr> <td class="indent1">Perindopril</td> <td>Aceon</td> <td>4 to 8 (maximum 16 mg)</td> </tr> <tr> <td class="indent1">Quinapril</td> <td>Accupril</td> <td>10 to 40</td> </tr> <tr> <td class="indent1">Ramipril</td> <td>Altace</td> <td>2.5 to 10 (maximum 20 mg)</td> </tr> <tr> <td class="indent1">Trandolapril</td> <td>Mavik</td> <td>1 to 4 (maximum 8 mg)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Angiotensin II receptor antagonists</td> </tr> <tr> <td class="indent1">Azilsartan</td> <td>Edarbi</td> <td>80</td> </tr> <tr> <td class="indent1">Candesartan</td> <td>Atacand</td> <td>8 to 32</td> </tr> <tr> <td class="indent1">Eprosartan</td> <td>Teveten</td> <td>600 to 800</td> </tr> <tr> <td class="indent1">Irbesartan</td> <td>Avapro</td> <td>150 to 300</td> </tr> <tr> <td class="indent1">Losartan</td> <td>Cozaar</td> <td>50 to 100</td> </tr> <tr> <td class="indent1">Olmesartan</td> <td>Benicar</td> <td>20 to 40</td> </tr> <tr> <td class="indent1">Telmisartan</td> <td>Micardis</td> <td>40 to 80</td> </tr> <tr> <td class="indent1">Valsartan</td> <td>Diovan</td> <td>80 to 320</td> </tr> </tbody></table></div><div class="graphic_footnotes">* Doses as low as one-half or one-quarter of the lower dose shown may be used initially in high-risk patients such as those with heart failure, significant renal insufficiency, hyponatremia, intravascular volume depletion, or those receiving concurrent treatment with a diuretic.<br/>¶ Giving one-half the dose twice a day is an alternative that produces a lesser peak effect but a more sustained response; however, patient compliance may be reduced. In patients who do not respond to a moderate dose, we suggest sequential monotherapy for optimizing initial drug selection in most patients rather than use of maximum doses shown in this table. Refer to discussion in UpToDate topic review of choice of drug therapy in primary hypertension for detail.<br/>Δ Not available in US.</div><div class="graphic_reference">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved and Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14.</div><div id="graphicVersion">Graphic 64770 Version 20.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
